Article Details
Retrieved on: 2024-09-17 21:44:59
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
ArriVent BioPharma's lead molecule, firmonertinib, targets NSCLC with EGFR Exon 20 insertion mutations and shows potential in both classical and ...
Article found on: seekingalpha.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here